Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2025-04.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Epidemiol Health > Volume 45; 2023 > Article
COVID-19
Original Article
 Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
Mi-Sook Kim1*orcid, Bongyoung Kim2*orcid, Jeong Pil Choi3orcid, Nam-Kyong Choi4orcid, Jung Yeon Heo5orcid, Jun Yong Choi6orcid, Joongyub Lee3orcid, Sang Il Kim7orcid
Epidemiol Health 2023;45:e2023090.
DOI: https://doi.org/10.4178/epih.e2023090
Published online: October 13, 2023

1Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea

2Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

3Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea

4Department of Health Convergence, Ewha Womans University, Seoul, Korea

5Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea

6Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, Korea

7Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence: Joongyub Lee Department of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea E-mail: c5cktail@snu.ac.kr
Co-correspondence: Sang Il Kim Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea E-mail: drksi@catholic.ac.kr
*Kim & Kim contributed equally to this work as joint first authors.
• Received: July 14, 2023   • Accepted: September 22, 2023

© 2023, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 8,188 Views
  • 171 Download
Full Article

Download PDF Download PDF

  • OBJECTIVES
    To assess the risk of lymphadenopathy following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.
  • METHODS
    A self-controlled case series design was used to determine whether the risk of lymphadenopathy was higher in the 1-day to 42-day risk interval after coronavirus disease 2019 (COVID-19) vaccination compared to the control period. In addition, subgroup analyses were conducted according to baseline characteristics, time since vaccination, and sensitivity analyses adjusted for the length of the risk interval.
  • RESULTS
    The risk of developing lymphadenopathy in the risk interval (1-42 days) after COVID-19 vaccination compared to the control period was significantly increased, with a relative incidence (RI) of 1.17 (95% confidence interval [CI], 1.17 to 1.18) when the first, second, and third doses were combined. The RI was greater on the day of vaccination (1.47; 95% CI, 1.44 to 1.50). In subgroup analyses by baseline characteristics, a significantly increased risk or trend toward increased risk was observed in most subgroups except for those aged 70 years and older, with a significant increase in risk in younger individuals, those with a Charlson’s comorbidity index <5, and those who received mRNA vaccines (mRNA-1273>BNT162b2). Within the 1-day to 42-day post-dose risk period, the relative risk was highest during the 1-day to 7-day post-dose period (1.59; 95% CI, 1.57 to 1.60) compared to the control period, and then the risk declined. In the sensitivity analysis, we found that the longer the risk window, the smaller the RI.
  • CONCLUSIONS
    SARS-CoV-2 vaccination is associated with a statistically significant increase in the risk of lymphadenopathy, and this risk was observed only with mRNA vaccines.
  • Keywords: COVID-19 vaccines, Lymphadenopathy, Self-controlled case series, Vaccine safety
A lymph node (LN) is a small gland that filters lymph, a fluid that circulates in the lymphatic system, and is the site of maturation of lymphocytes [1]. Lymphadenopathy, which refers to an abnormality in LN size and consistency, can occur due to various reasons, including bacterial, viral, or fungal infections, autoimmune disorders, and malignancies [2]. Reports have surfaced indicating the occurrence of lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination, which is thought to occur as the vaccine components enter the LNs through the lymphatic system and generate an immune reaction, causing proliferation of lymphocytes [3]. The S-specific TFH cell response in axillary LN fine-needle biopsies from 15 individuals in the clinical trial of the BNT162b2 vaccine could be interpreted as mechanistic evidence that lymphadenopathy can be induced as part of the normal immune response to vaccination [4]. Furthermore, the observation of S-binding germinal center B cells and plasmablasts in the draining LNs after a booster dose of the BNT162b2 vaccine provides the same rationale for lymphadenopathy due to the booster vaccination [5].
During the clinical trials of the mRNA-1273 vaccine, 11.6% of patients (5.0% placebo) experienced axillary swelling or tenderness after the first dose, and 16.0% (4.3% placebo) after the second dose. Considering a previous study reporting that 4.8% (4/83) of patients with influenza vaccination had axillary lymphadenopathy, COVID-19 vaccines may be associated with a higher incidence of lymphadenopathy than other vaccines [6]. Another study revealed that the pooled prevalence of axillary lymphadenopathy after COVID-19 vaccination was 37% (95% confidence interval [CI], 27 to 47) on positron emission tomography/computed tomography [7]. Furthermore, in a prospective observational study conducted in Jordan, the incidence of lymphadenopathy within 14 days of COVID-19 vaccination was 157.9 per 100,000, the highest of the 18 red-flag outcomes analyzed [8]. Hence, lymphadenopathy could be regarded as a common adverse event of COVID-19 vaccination.
While some studies have reported that there was no association between COVID-19 vaccination and the development of lymphadenopathy [9], a few studies have demonstrated an increase in lymphadenopathy caused by COVID-19 vaccines [10-12]. However, no previous studies have adopted the self-controlled case series (SCCS) design which was originally developed for the evaluation of vaccine safety [13]. Therefore, this study applied an SCCS design, aiming to determine whether there was an association between COVID-19 vaccination and the incidence of lymphadenopathy, and to clarify the clinical characteristics of lymphadenopathy that might occur after COVID-19 vaccination.
Data source
This study was conducted using data from the National Health Insurance Service (NHIS) during the period from January 1, 2020 to December 31, 2021. The NHIS is a comprehensive national health insurance system that encompasses all citizens of the Korea and provides patient demographic, diagnostic, procedural, operative, and prescription data from all insurance claims, which are used for research purposes [14]. The Korea Disease Control and Prevention Agency (KDCA) used a linkage key of national identification numbers to connect its COVID-19 confirmed case and vaccination databases with the NHIS data. The immunization database linked by the KDCA contains information on the date of vaccination, the type of vaccine administered, and the dosage [15]. The COVID-19 confirmed case database includes the COVID-19 diagnosis date, death status, and date of death.
Upon integration of the NHIS and KDCA databases, unique study identification numbers were assigned to replace the national identification numbers. Subsequently, the data were rendered de-identified and access was restricted to authorized analysts only through an NHIS-controlled remote data analysis system.
Inclusion/exclusion criteria of patients for the case-only study design
The SCCS design is a patient-only study design utilized to assess the causal contribution of COVID-19 vaccination to lymphadenopathy while controlling the bias from unmeasured time-invariant confounders [16]. Before applying the SCCS design, it is necessary to consider whether there is an event-related exposure or an event-related observation period [17]. Lymphadenopathy is usually temporary and exhibits mild symptoms that do not warrant discontinuation of vaccination. Moreover, deaths among patients with a claimed diagnosis of lymphadenopathy are frequently due to comorbidities that cause the lymphadenopathy, not the lymphadenopathy itself. Therefore, the standard SCCS approach was selected, assuming no relationship between death and lymphadenopathy, with follow-up censored at the time of death. The study included patients aged 18 years or older, regardless of COVID-19 vaccination status, who received medical care for lymphadenopathy between January 1, 2021 and December 31, 2021. Unvaccinated individuals were primarily included to account for seasonal effects in the analysis. The exclusion criteria were as follows: (1) patients with a history of lymphadenopathy in the previous 1 year; (2) patients with a presumptive diagnosis of the cause of lymphadenopathy within 3 months of the diagnosis of lymphadenopathy or within 12 months before the diagnosis, such as tuberculosis, plague, tularemia, chlamydial infection, human immunodeficiency virus, sporotrichosis, malignant neoplasm, hemangioma and lymphangioma, other neoplasms of lymphoid, hematopoietic tissue, sarcoidosis, and postmastectomy lymphedema syndrome; (3) patients with confirmed COVID-19; (4) patients whose COVID-19 vaccination records in the database of the KDCA were missing; (5) patients vaccinated through clinical trials; and (6) patients with 2 or more vaccination records within a single dose, or if the chronological order of vaccination series was reversed.
Variables
The primary outcome variable was a healthcare visit due to lymphadenopathy, and the operational definition of lymphadenopathy in the NHIS database was determined by consensus of a panel of experts from the National Academy of Medicine of Korea as a claim with International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) codes: D36.0, I88.x, I89.x, L04.x, and R59.x. The study utilized the KDCA database to confirm the exposure to the COVID-19 vaccine, and it was confirmed that the ChAdOx1, BNT162b2, Ad26. COV2.S, and mRNA-1273 vaccines were administered during the study period. Using data from 2021, patients were categorized into age groups of 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or older. Charlson’s comorbidity index (CCI) was also utilized to identify 19 comorbidities and weight them in order to divide patients into two groups: those with a score of 0-4 or 5 or more [18]. The comorbidities considered in the stratification analysis and those considered for exclusion were defined using ICD-10 codes and are presented in Supplementary Material 1.
Statistical analysis
A summary of the baseline characteristics of the study population was presented by the timing of lymphadenopathy: those experiencing lymphadenopathy on the vaccination day, those developing it in the risk period (between days 1 and 42 after vaccination), and those experiencing it during the remaining period of the observation period of 365 days in 2021, which served as the control period. The length of the risk period was chosen to be 42 days because previous mRNA vaccine safety assessment studies have used a 42-day adverse event observation period [10], and because magnetic resonance imaging (MRI)-based axillary lymphadenopathy studies have shown that the prevalence of lymphadenopathy between 29-42 days after mRNA vaccination is 3 times higher than the baseline level [19]. Descriptive statistics were used to summarize categorical variables in terms of frequencies and percentages, while means and standard deviations were used to summarize continuous variables. The relative incidence (RI) of lymphadenopathy on the vaccination day (day 0) and during the risk period (days 1-42) was calculated using a conditional Poisson regression model. The potential influence of seasonality was controlled by including twelve 30-day calendar periods in the model. The combined effect of all three vaccine doses was also presented for each vaccine dose. Furthermore, we evaluated changes in the risk of lymphadenopathy over time from the vaccination date within the risk period (for days 1-7, 8-14, 15-28, and 29-42) by dose and combined effect.
Subgroup analyses were conducted to investigate the associations of baseline characteristics and vaccine types with the risk of lymphadenopathy on the vaccination day and during days 1-42. For the analysis by vaccine type, patients who received only one of the three types of vaccines—ChAdOx1, BNT162b2, or mRNA-1273—were included. In addition, the study evaluated changes in the RI with 7-day increases in the length of the risk period, ranging from 21 days to 63 days, for each dose and combined effect. All statistical analyses were performed using SAS Enterprise Guide 7.4 (SAS Institute Inc., Cary, NC, USA) and R version 4.1.3 (R Foundation for Statistical Computing, Vienna, Austria).
Ethics statement
The study received ethical approval from the common institutional review board in Korea under the reference P01-202203-01-005, and written informed consent was waived for this study, because only de-identified data were used.
Characteristics of the study subjects
Between January 2021 and December 2021, a substantial cohort of 1,356,987 patients received billing for lymphadenopathy-related diagnoses. Following exclusionary measures, 831,902 individuals were deemed eligible for analysis to explore the potential association between COVID-19 vaccination and lymphadenopathy. Among these subjects, 784,093 had been vaccinated against COVID-19, while 47,809 remained unvaccinated (Figure 1).
The characteristics of patient demographics are shown in Table 1. The results indicated a decline in the proportion of adverse events with advancing age, with 7.9% of cases reported in patients in their 70s and 4.3% in those aged 80 years or above. Female represented the majority of cases, accounting for 65.2%. The prevalence of hypertension, diabetes mellitus, and hyperlipidemia were 24.1%, 16.3%, and 33.8%, respectively. Most patients (95.9%) had a CCI, score of 0-4. In regards to vaccination, the most common regimen consisted of two doses of BNT162b2, followed by three doses of BNT162b2, two doses of mRNA-1273, and two doses of ChAdOx1 with a third dose of mRNA-1273, which accounted for 35.2%, 16.8%, 13.7%, and 10.1% of the patients, respectively. Fewer than 10% of cases had received one or fewer vaccinations, while 53.5% had received two vaccinations.
The length of the risk period and control period were 34.4±11.3 days and 286.0±26.2 days, respectively (Supplementary Material 2). The proportions of events were 24.3%, 74.8%, and 0.9% and the incidence rates per 1 person-year were 1.16 (95% CI, 1.16 to 1.17), 0.96 (95% CI, 0.95 to 0.96), and 1.46 (95% CI, 1.42 to 1.49) in the risk period, control periods, and the date of the vaccination, respectively (Table 1, Supplementary Material 2). Individuals with lymphadenopathy at the time of vaccination were found to have a higher proportion of being in the age range of 50 years to 60 years, male, and having received mRNA-1273 as their third dose following initial ChAdOx1 vaccination, in comparison to those who experienced lymphadenopathy during the risk or control periods. These observations were made through an analysis and comparison of data sets.
The association between the coronavirus disease 2019 vaccine and the incidence of lymphadenopathy
The RI of lymphadenopathy increased with three successive vaccine doses. Among the administered doses, dose 3 demonstrated the highest RI (1.26; 95% CI, 1.24 to 1.28). The combined effect of vaccination on the incidence of lymphadenopathy was shown by an RI of 1.17 (95% CI, 1.17 to 1.18; Table 2) In addition, the relative risk of lymphadenopathy was observed to be higher on the day of vaccination than in the 1-42 days after vaccination with a combined effect of 1.47 (95% CI, 1.44 to 1.50). Stratifying the changing risk of lymphadenopathy over time from the day of vaccination, we observed an increasing risk with three successive doses only in the 1-day to 7-day period after vaccination (Table 3). Moreover, the risk of lymphadenopathy decreased with an increase in the time elapsed from the day of vaccination. The combined effect of the risk was estimated to be 1.59 (95% CI, 1.57 to 1.60), 1.18 (95% CI, 1.17 to 1.20), 1.04 (95% CI, 1.03 to 1.05), and 1.01 (95% CI, 1.00 to 1.02) for days 1-7, days 8-14, days 15-28, and days 29-42, respectively.
Subgroup analysis and sensitivity analysis
The increased risk of lymphadenopathy with COVID-19 vaccination was statistically significant for age groups from the 20s through 60s, but no significant risk was observed in individuals over the age of 70. The increased risk was significant in both sexes, with females tending to present a greater risk. Moreover, the comorbidity index was found to be a significant factor, with an RI of 1.18 (95% CI, 1.17 to 1.19) for a comorbidity index of 0-4, and a non-significant RI of 1.02 (95% CI, 0.99 to 1.05) for a comorbidity index of 5 or more. An analysis of the combined effect of ChAdOx1 vaccines showed an RI of 1.01 (95% CI, 0.98 to 1.04), while the highest risk was associated with mRNA-1273 vaccines (RI, 1.43; 95% CI, 1.40 to 1.45) and BNT162b2 vaccines (RI, 1.19; 95% CI, 1.18 to 1.20; Table 4) A sensitivity analysis to assess the impact of the size of the risk window on the findings demonstrated a gradual decrease in the combined RI from 1.28 (95% CI, 1.28 to 1.29) to 1.14 (95% CI, 1.13 to 1.14) as the length of the risk window rose from 21 days to 63 days (Table 5).
Our analysis revealed a statistically significant elevation in the risk of lymphadenopathy during the period of 1-42 days following vaccination. The risk was found to be significant only for the mRNA platform vaccines, such as BNT162b2 and mRNA-1273, and not for viral vector vaccines. The RI tended to be greater in younger and female individuals, as well as those receiving the third dose compared to the first dose. The highest risk was noted on the day of vaccination, although there was unclear temporal relationship between the vaccination and incidence. During the risk period, the RI for lymphadenopathy was highest in the first week, then declined gradually over time. The decreasing RI approached 1.00 by the end of the second week post-vaccination, indicating a negligible magnitude of lymphadenopathy risk in spite of the statistical significance.
As of October 31, 2021, a total of 39,739,672 individuals had received COVID-19 vaccines in Korea. In this study, 209,833 cases with lymphadenopathy within 42 days after vaccination were identified, accounting for 0.5%. While this proportion is considerably lower than the reported incidence of radiologically detectable lymphadenopathy (9-54%) [20], it aligns with a study that reported the incidence of clinically detectable lymphadenopathy to be 0.4% [21].
The characteristics of lymphadenopathy observed in our analysis are in line with studies that have investigated lymphadenopathy following COVID-19 vaccination. A prospective evaluation of MRI scans before and after administration of the COVID-19 vaccine revealed that being female, and having a younger age were identified as predisposing factors for vaccination-related axillary lymphadenopathy in individuals who received two doses of either the BNT162b2 or mRNA-1273 vaccine [19]. Lymphadenopathy risk decreased gradually at 2 weeks post-vaccination [19]. A survey performed in Vietnam found that recipients of the third dose of COVID-19 vaccines had a significantly higher odds ratio of experiencing lymphadenopathy within 14 days of vaccination than those who received the first and second doses [22]. A meta-analysis of studies reporting adverse events following COVID-19 vaccination in Saudi Arabia demonstrated that the risk of lymphadenopathy was significantly higher with BNT162b2 than with ChAdOx1 [23].
Previous studies evaluating the causal relationship between the administration of mRNA-based COVID-19 vaccines and lymphadenopathy also reported similar results to our study. In a phase 3 clinical trial conducted in the United States involving 30,351 individuals who received the mRNA-1273 vaccine or a placebo, axillary swelling or tenderness was evaluated within 7 days of vaccination. The incidence was notably higher in the mRNA-1273 vaccinated group, with rates of 10.2% and 14.2% observed after the first and second doses compared to the control group, with rates of 4.8% and 3.9% after the first and second doses, respectively. The mean time to outcome for the vaccinated group was 2.3 days after the first dose and 2.4 days after the second dose [11]. Furthermore, a targeted trial emulation analysis of 823,006 individuals vaccinated with BNT162b2 and 823,006 unvaccinated individuals in Israel demonstrated a significantly higher risk of lymphadenopathy within 42 days of vaccination in the vaccinated group (2.43; 95% CI, 2.05 to 2.78) [10]. Finally, a selfcontrolled risk interval analysis of electronic health record data from 47,999 individuals who received three doses of mRNA vaccines in the United States revealed a significantly increased risk of lymphadenopathy, with a higher proportion of individuals experiencing this condition after the third dose compared to the second dose [12].
The biological mechanism of COVID-19 vaccine-associated lymphadenopathy has not been conclusively established, but it is primarily considered to be attributed to reactive hyperplasia, characterized by the rapid expansion of T and B cells. The mRNA vaccine exhibited greater potency in generating antigen-specific antibodies and T cell responses than the adenovirus vector vaccine [20]. This supports the disparity in the risk of lymphadenopathy between vaccine platforms.
The present study offered notable advantages in terms of high internal validity by employing statistical analysis techniques to adjust for all time-invariant confounders. The external validity of this study is also strengthened by including all cases of lymphadenopathy that occurred during the study period. However, the findings of this study must be interpreted considering the following limitations. Firstly, with respect to the increased risk observed on the day of vaccination, data to determine whether vaccination or lymphadenopathy occurred first were not available from the NHIS database. We found a trend toward increased risk closer to the timing of vaccination, but the risk on the day of vaccination should be interpreted with caution. Secondly, the immune response triggered by vaccine components might have resulted in swelling of the axillary LNs, which are nearest to the usual vaccination site. However, since the specific location of the lymphadenopathy (i.e., cervical, inguinal, or axillary) was not available in the data, there was a potential for overestimating the causal association by including lymphadenopathy as an outcome within the risk period. Thirdly, all cases of lymphadenopathy, regardless of severity, for which patients visited healthcare providers were included in the study’s outcome. Therefore, it remained uncertain whether mild cases of lymphadenopathy within the range of the normal immune response should be classified as adverse events. In relation to severe cases, the diagnostic, therapeutic, and prognostic processes might be of clinical interest, but were not addressed in this study, highlighting the need for further investigation.
In conclusion, there has been a significant increase in the incidence of lymphadenopathy associated with COVID-19 vaccination. Moreover, research has shown that the risk of lymphadenopathy is significant only for mRNA platform vaccines, not for viral vector vaccines, and it is higher among younger people and females. These findings suggest a possible epidemiologic causal relationship, while they also challenge healthcare providers to differentiate between lymphadenopathy caused by an immune response to mRNA vaccines and that caused by a pathologic process.
Supplementary materials are available at https://www.e-epih.org/.

Supplement Material 1.

List of ICD-10 codes for variables
epih-45-e2023090-Supplementary-1.docx

Supplement Material 2.

Follow-up duration, number of events, and incidence rate (per 1 person-year) of lymphadenopathy by period
epih-45-e2023090-Supplementary-2.docx

DATA AVAILABILITY

The data used in this analysis were obtained through the KDCA and are not publicly available. Interested researchers may contact KDCA to apply to gain access to the data.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare for this study.

FUNDING

This study was sponsored by the KDCA (project No. 2021-05008).

AUTHOR CONTRIBUTIONS

Conceptualization: Lee J, Kim SI, Kim MS, Kim B. Data curation: Lee J, Kim MS. Formal analysis: Lee J, Kim MS. Funding acquisition: Lee J. Methodology: Lee J, Kim SI, Kim MS, Kim B, Choi JP, Choi NK, Heo JY, Choi JY. Project administration: Lee J, Kim SI. Visualization: Lee J, Kim MS. Writing-original draft: Lee J, Kim SI, Kim MS, Kim B. Writing-review & editing: Lee J, Kim SI, Kim MS, Kim B, Choi JP, Choi NK, Heo JY, Choi JY.

We thank the COVID-19 Vaccine Safety Research Committee (CoVaSC) for linking KDCA’s COVID-19 vaccination data with the National Health Insurance Service’s claims data. We are very grateful to the COVID-19 Vaccine Safety Research Center of the National Academy of Medicine of Korea for their administrative support during the analysis period.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Figure 1.
Flow chart of subject selection. COVID-19, coronavirus disease 2019.
epih-45-e2023090f1.jpg
Table 1.
Characteristics of patient demographics in relation to the incidence of lymphadenopathy during the risk and control periods after coronavirus disease 2019 vaccination
Characteristics Total Events on day 0 Events in risk period Events in control period
Total (n) 831,902 7,417 202,466 622,019
Age (yr)
 Mean±SD 46.9±17.9 47.7±16.6 47.3±17.6 46.7±18.0
 18-29 178,417 (21.5) 1,397 (18.8) 41,009 (20.3) 136,011 (21.9)
 30-39 142,069 (17.1) 1,140 (15.4) 33,546 (16.6) 107,383 (17.3)
 40-49 151,429 (18.2) 1,344 (18.1) 38,079 (18.8) 112,006 (18.0)
 50-59 140,421 (16.9) 1,549 (20.9) 35,668 (17.6) 103,204 (16.6)
 60-69 118,207 (14.2) 1,306 (17.6) 29,856 (14.8) 87,045 (14.0)
 70-79 65,641 (7.9) 476 (6.4) 16,288 (8.0) 48,877 (7.9)
 ≥80 35,718 (4.3) 205 (2.8) 8,020 (4.0) 27,493 (4.4)
Sex
 Male 289,192 (34.8) 2,802 (37.8) 67,813 (33.5) 218,577 (35.1)
 Female 542,710 (65.2) 4,615 (62.2) 134,653 (66.5) 403,442 (64.9)
Comorbidities
 Hypertension 200,650 (24.1) 1,890 (25.5) 49,238 (24.3) 149,522 (24.0)
 Diabetes mellitus 135,691 (16.3) 1,225 (16.5) 33,038 (16.3) 101,428 (16.3)
 Hyperlipidemia 280,907 (33.8) 2,571 (34.7) 69,941 (34.5) 208,395 (33.5)
Charlson comorbidity index
 Mean±SD 1.0±1.5 1.0±1.5 1.0±1.5 1.0±1.5
 0-4 797,495 (95.9) 7,138 (96.2) 194,346 (96.0) 596,011 (95.8)
 ≥5 34,407 (4.1) 279 (3.8) 8,120 (4.0) 26,008 (4.2)
Type of vaccination
 ChAd 1,317 (0.2) 4 (0.1) 301 (0.2) 1,012 (0.2)
 ChAd/ChAd 24,550 (3.0) 194 (2.6) 5,690 (2.8) 18,666 (3.0)
 ChAd/ChAd/ChAd 4 (0.0) 1 (0.0) (0.0) 3 (0.0)
 ChAd/ChAd/mRNA-1273 84,003 (10.1) 978 (13.2) 23,133 (11.4) 59,892 (9.6)
 ChAd/ChAd/BNT 47,881 (5.8) 502 (6.8) 14,207 (7.0) 33,172 (5.3)
 ChAd/mRNA-1273 3 (0.0) - 2 (0.0) 1 (0.0)
 ChAd/mRNA-1273/mRNA-1273 4 (0.0) - - 4 (0.0)
 ChAd/BNT 12,038 (1.5) 97 (1.3) 3,169 (1.6) 8,772 (1.4)
 ChAd/BNT/mRNA-1273 191 (0.0) 1 (0.0) 54 (0.0) 136 (0.0)
 ChAd/BNT/BNT 25,677 (3.1) 282 (3.8) 7,934 (3.9) 17,461 (2.8)
 Ad26 2,428 (0.3) 15 (0.2) 320 (0.2) 2,093 (0.3)
 Ad26/BNT 2 (0.0) - - 2 (0.0)
 mRNA-1273 3,607 (0.4) 10 (0.1) 951 (0.5) 2,646 (0.4)
 mRNA-1273/ChAd 1 (0.0) - - 1 (0.0)
 mRNA-1273/mRNA-1273 113,777 (13.7) 1,084 (14.6) 31,282 (15.5) 81,411 (13.1)
 mRNA-1273/mRNA-1273/mRNA-1273 17,181 (2.1) 206 (2.8) 4,887 (2.4) 12,088 (1.9)
 mRNA-1273/mRNA-1273/BNT 1,266 (0.2) 7 (0.1) 410 (0.2) 849 (0.1)
 mRNA-1273/BNT 2,142 (0.3) 23 (0.3) 537 (0.3) 1,582 (0.3)
 BNT 15,368 (1.9) 82 (1.1) 1,818 (0.9) 13,468 (2.2)
 BNT/ChAd 3 (0.0) - 1 (0.0) 2 (0.0)
 BNT/ChAd/BNT 1 (0.0) - - 1 (0.0)
 BNT/Ad26 1 (0.0) - 1 (0.0) -
 BNT/mRNA-1273 2 (0.0) - - 2 (0.0)
 BNT/BNT 292,703 (35.2) 2,623 (35.4) 70,483 (34.8) 219,597 (35.3)
 BNT/BNT/mRNA-1273 560 (0.1) 4 (0.1) 134 (0.1) 422 (0.2)
 BNT/BNT/BNT 139,382 (16.8) 1,303 (17.6) 37,152 (18.4) 100,927 (16.2)
Vaccine doses
 No vaccination 47,809 (5.8) - - 47,809 (7.7)
 1st dose only 22,720 (2.7) 111 (1.5) 3,390 (1.7) 19,219 (3.1)
 2nd dose 445,222 (53.5) 4,021 (54.2) 111,165 (54.9) 330,036 (53.1)
 3rd dose 316,151 (38.0) 3,285 (44.3) 87,911 (43.4) 224,955 (36.2)

Values are presented as number (%).

ChAd, ChAdOx1; BNT, BNT162b2; Ad26, Ad26.COV2.S; SD, standard deviation.

Table 2.
Risk of lymphadenopathy by coronavirus disease 2019 vaccination
Period Dose 1 Dose 2 Dose 3 Combined effect
Control period 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Day 0 1.35 (1.30, 1.40) 1.53 (1.48, 1.59) 1.60 (1.51, 1.68) 1.47 (1.44, 1.50)
Day 1 to 42 1.19 (1.18, 1.20) 1.15 (1.14, 1.16) 1.26 (1.24, 1.28) 1.17 (1.17, 1.18)

Values are presented as relative incidence (95% confidence interval).

Table 3.
The risk of developing lymphadenopathy after coronavirus disease 2019 vaccination by time since vaccination
Risk-period (day) Dose 1 Dose 2 Dose 3 Combined effect
1 to 7 1.37 (1.35, 1.39) 1.77 (1.74, 1.79) 1.72 (1.68, 1.75) 1.59 (1.57, 1.60)
8 to 14 1.42 (1.40, 1.44) 1.02 (1.00, 1.04) 0.94 (0.91, 0.97) 1.18 (1.17, 1.20)
15 to 28 1.07 (1.06, 1.09) 1.03 (1.02, 1.04) 0.95 (0.92, 0.98) 1.04 (1.03, 1.05)
29 to 42 1.03 (1.01, 1.05) 1.00 (0.99, 1.02) 0.89 (0.83, 0.94) 1.01 (1.00, 1.02)

Values are presented as relative incidence (95% confidence interval).

Table 4.
Subgroup analysis on the risk of lymphadenopathy after coronavirus disease 2019 vaccination
Subgroup Dose 1
 Dose 2
 Dose 3
 Combined dose
Day 0 Day 1-42 Day 0 Day 1-42 Day 0 Day 1-42 Day 0 Day 1-42
Age (yr)
 18-29 1.32 (1.22, 1.43) 1.25 (1.22, 1.27) 1.48 (1.37, 1.60) 1.16 (1.14, 1.18) 1.58 (1.33, 1.87) 2.19 (2.09, 2.29) 1.42 (1.34, 1.49) 1.23 (1.21, 1.25)
 30-39 1.53 (1.40, 1.67) 1.36 (1.33, 1.38) 1.69 (1.55, 1.84) 1.28 (1.26, 1.30) 1.83 (1.50, 2.24) 1.91 (1.81, 2.03) 1.62 (1.53, 1.72) 1.33 (1.31, 1.35)
 40-49 1.53 (1.41, 1.66) 1.22 (1.20, 1.25) 1.72 (1.59, 1.86) 1.27 (1.25, 1.30) 1.31 (1.08, 1.57) 2.01 (1.91, 2.10) 1.60 (1.52, 1.69) 1.28 (1.26, 1.30)
 50-59 1.47 (1.35, 1.59) 1.13 (1.11, 1.15) 1.92 (1.77, 2.07) 1.14 (1.12, 1.16) 1.86 (1.66, 2.09) 1.59 (1.53, 1.66) 1.73 (1.65, 1.82) 1.18 (1.16, 1.20)
 60-69 1.23 (1.11, 1.36) 0.99 (0.97, 1.02) 1.53 (1.40, 1.68) 1.02 (0.99, 1.04) 1.73 (1.57, 1.90) 1.03 (1.00, 1.07) 1.48 (1.40, 1.56) 1.01 (1.00, 1.03)
 70-79 0.70 (0.58, 0.83) 0.97 (0.94, 1.00) 0.78 (0.66, 0.92) 0.98 (0.95, 1.00) 1.37 (1.19, 1.57) 0.96 (0.92, 1.00) 0.92 (0.84, 1.01) 0.97 (0.95, 0.99)
 ≥80 0.45 (0.33, 0.60) 0.92 (0.87, 0.96) 0.54 (0.41, 0.70) 0.96 (0.92, 1.00) 1.53 (1.26, 1.85) 0.96 (0.91, 1.01) 0.77 (0.67, 0.88) 0.95 (0.92, 0.98)
Sex
 Male 1.48 (1.40, 1.58) 1.11 (1.10, 1.13) 1.65 (1.56, 1.75) 1.14 (1.13, 1.16) 1.74 (1.60, 1.89) 1.18 (1.15, 1.22) 1.60 (1.54, 1.66) 1.13 (1.12, 1.15)
 Female 1.28 (1.22, 1.34) 1.23 (1.21, 1.24) 1.47 (1.41, 1.54) 1.15 (1.14, 1.16) 1.52 (1.42, 1.62) 1.30 (1.28, 1.33) 1.40 (1.36, 1.44) 1.19 (1.19, 1.20)
Comorbidities
 Hypertension 1.16 (1.07, 1.25) 1.06 (1.04, 1.08) 1.29 (1.19, 1.39) 1.06 (1.04, 1.08) 1.63 (1.50, 1.77) 0.98 (0.95, 1.01) 1.33 (1.27, 1.39) 1.05 (1.04, 1.06)
 Diabetes mellitus 1.16 (1.05, 1.28) 1.06 (1.04, 1.08) 1.26 (1.15, 1.38) 1.07 (1.05, 1.09) 1.53 (1.38, 1.70) 0.96 (0.93, 0.99) 1.29 (1.22, 1.37) 1.05 (1.03, 1.06)
 Dyslipidemia 1.19 (1.11, 1.27) 1.11 (1.09, 1.12) 1.34 (1.26, 1.43) 1.09 (1.07, 1.10) 1.59 (1.47, 1.71) 1.04 (1.01, 1.06) 1.34 (1.29, 1.39) 1.09 (1.08, 1.10)
Charlson comorbidity index
 0-4 1.37 (1.32, 1.42) 1.19 (1.18, 1.20) 1.55 (1.50, 1.61) 1.15 (1.14, 1.16) 1.60 (1.51, 1.69) 1.30 (1.28, 1.32) 1.48 (1.45, 1.52) 1.18 (1.17, 1.19)
 ≥5 0.96 (0.77, 1.18) 1.03 (0.99, 1.08) 1.04 (0.85, 1.28) 1.04 (1.00, 1.08) 1.62 (1.33, 1.97) 0.96 (0.90, 1.03) 1.16 (1.03, 1.31) 1.02 (0.99, 1.05)
Type of vaccination
 ChAdOx1 1.41 (1.16, 1.70) 1.01 (0.97, 1.05) 1.36 (1.11, 1.67) 1.01 (0.97, 1.05) N/A N/A 1.39 (1.21, 1.60) 1.01 (0.98, 1.04)
 mRNA-1273 1.54 (1.42, 1.68) 1.59 (1.56, 1.62) 2.11 (1.95, 2.27) 1.28 (1.25, 1.30) 1.55 (1.21, 1.98) 1.78 (1.64, 1.94) 1.78 (1.69, 1.89) 1.43 (1.40, 1.45)
 BNT162b2 1.36 (1.29, 1.42) 1.14 (1.12, 1.15) 1.5 (1.43, 1.57) 1.19 (1.18, 1.20) 1.58 (1.46, 1.72) 1.41 (1.38, 1.45) 1.45 (1.41, 1.50) 1.19 (1.18, 1.20)

Values are presented as relative incidence (95% confidence interval).

N/A, not available.

Table 5.
Sensitivity analysis of lymphadenopathy risk by the length of the risk window
Risk window RI (95% CI) for day 1-42
Dose 1 Dose 2 Dose 3 Combined effect
Days 21 1.29 (1.28, 1.30) 1.27 (1.26, 1.28) 1.31 (1.29, 1.33) 1.28 (1.28, 1.29)
Days 28 1.23 (1.22, 1.25) 1.21 (1.20, 1.22) 1.28 (1.26, 1.31) 1.23 (1.22, 1.24)
Days 35 1.20 (1.20, 1.21) 1.17 (1.17, 1.18) 1.27 (1.25, 1.29) 1.20 (1.19, 1.20)
Days 42 1.19 (1.18, 1.20) 1.15 (1.14, 1.16) 1.26 (1.24, 1.28) 1.17 (1.17, 1.18)
Days 49 1.18 (1.17, 1.19) 1.13 (1.12, 1.14) 1.26 (1.24, 1.28) 1.16 (1.15, 1.17)
Days 56 1.17 (1.16, 1.18) 1.11 (1.11, 1.12) 1.27 (1.25, 1.29) 1.15 (1.14, 1.15)
Days 63 1.16 (1.15, 1.17) 1.10 (1.10, 1.11) 1.27 (1.25, 1.29) 1.14 (1.13, 1.14)

RI, relative incidence; CI, confidence interval.

  • 1. Shang T, Liang J, Kapron CM, Liu J. Pathophysiology of aged lymphatic vessels. Aging (Albany NY) 2019;11:6602-6613.ArticlePubMedPMC
  • 2. Gaddey HL, Riegel AM. Unexplained lymphadenopathy: evaluation and differential diagnosis. Am Fam Physician 2016;94:896-903.PubMed
  • 3. Miyasaka M. The lymphatic system and COVID-19 vaccines. Front Immunol 2022;13:1041025.ArticlePubMedPMC
  • 4. Mudd PA, Minervina AA, Pogorelyy MV, Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 2022;185:603-613.ArticlePubMed
  • 5. Turner JS, O’Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021;596:109-113.ArticlePubMedPMCPDF
  • 6. Tu W, Gierada DS, Joe BN. COVID-19 vaccination-related lymphadenopathy: what to be aware of. Radiol Imaging Cancer 2021;3:e210038.ArticlePubMedPMC
  • 7. Treglia G, Cuzzocrea M, Giovanella L, Elzi L, Muoio B. Prevalence and significance of hypermetabolic lymph nodes detected by 2-[18F]FDG PET/CT after COVID-19 vaccination: a systematic review and a meta-analysis. Pharmaceuticals (Basel) 2021;14:762.ArticlePubMedPMC
  • 8. Abdel-Qader DH, Abdel-Qader H, Silverthorne J, Kongkaew C, Al Meslamani AZ, Hayajneh W, et al. Active safety surveillance of four types of COVID-19 vaccines: a national study from Jordan. Clin Drug Investig 2022;42:813-827.ArticlePubMedPMCPDF
  • 9. McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med 2021;2:965-978.ArticlePubMed
  • 10. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021;385:1078-1090.ArticlePubMed
  • 11. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416.PubMed
  • 12. Niesen MJ, Pawlowski C, O’Horo JC, Challener DW, Silvert E, Donadio G, et al. Surveillance of safety of 3 doses of COVID-19 mRNA vaccination using electronic health records. JAMA Netw Open 2022;5:e227038.ArticlePubMedPMC
  • 13. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995;51:228-235.ArticlePubMed
  • 14. Seong SC, Kim YY, Khang YH, Park JH, Kang HJ, Lee H, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol 2017;46:799-800.PubMed
  • 15. Jeong NY, Park H, Oh S, Jung SE, Kim DH, Shin HS, et al. A framework for nationwide COVID-19 vaccine safety research in the Republic of Korea: the COVID-19 Vaccine Safety Research Committee. Osong Public Health Res Perspect 2023;14:5-14.ArticlePubMedPMCPDF
  • 16. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 2016;354:i4515.ArticlePubMed
  • 17. Whitaker HJ, Ghebremichael-Weldeselassie Y, Douglas IJ, Smeeth L, Farrington CP. Investigating the assumptions of the self-controlled case series method. Stat Med 2018;37:643-658.ArticlePubMedPDF
  • 18. Christensen S, Johansen MB, Christiansen CF, Jensen R, Lemeshow S. Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin Epidemiol 2011;3:203-211.ArticlePubMedPMC
  • 19. Yoshikawa T, Miki S, Nakao T, Koshino S, Hayashi N, Abe O. Axillary lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 vaccination: MRI evaluation. Radiology 2023;306:270-278.ArticlePubMed
  • 20. Ho TC, Shen DH, Chang CC, Chan HP, Chuang KP, Yuan CH, et al. Immune response related to lymphadenopathy post COVID-19 vaccination. Vaccines (Basel) 2023;11:696.ArticlePubMedPMC
  • 21. Co M, Wong PC, Kwong A. COVID-19 vaccine associated axillary lymphadenopathy - a systematic review. Cancer Treat Res Commun 2022;31:100546.ArticlePubMedPMC
  • 22. Nguyen DC, Dao TL, Truong TM, Nguyen TH, Phan TN, Nguyen HM, et al. Short-term adverse effects immediately after the start of COVID-19 booster vaccination in Vietnam. Vaccines (Basel) 2022;10:1325.ArticlePubMedPMC
  • 23. Alhossan A, Alsaran AK, Almahmudi AH, Aljohani ZS, Albishi MR, Almutairi AK. Adverse events of COVID-19 vaccination among the Saudi population: a systematic review and meta-analysis. Vaccines (Basel) 2022;10:2089.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Figure
      • 0
      Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
      Image
      Figure 1. Flow chart of subject selection. COVID-19, coronavirus disease 2019.

      Figure 1.

      Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
      Characteristics Total Events on day 0 Events in risk period Events in control period
      Total (n) 831,902 7,417 202,466 622,019
      Age (yr)
       Mean±SD 46.9±17.9 47.7±16.6 47.3±17.6 46.7±18.0
       18-29 178,417 (21.5) 1,397 (18.8) 41,009 (20.3) 136,011 (21.9)
       30-39 142,069 (17.1) 1,140 (15.4) 33,546 (16.6) 107,383 (17.3)
       40-49 151,429 (18.2) 1,344 (18.1) 38,079 (18.8) 112,006 (18.0)
       50-59 140,421 (16.9) 1,549 (20.9) 35,668 (17.6) 103,204 (16.6)
       60-69 118,207 (14.2) 1,306 (17.6) 29,856 (14.8) 87,045 (14.0)
       70-79 65,641 (7.9) 476 (6.4) 16,288 (8.0) 48,877 (7.9)
       ≥80 35,718 (4.3) 205 (2.8) 8,020 (4.0) 27,493 (4.4)
      Sex
       Male 289,192 (34.8) 2,802 (37.8) 67,813 (33.5) 218,577 (35.1)
       Female 542,710 (65.2) 4,615 (62.2) 134,653 (66.5) 403,442 (64.9)
      Comorbidities
       Hypertension 200,650 (24.1) 1,890 (25.5) 49,238 (24.3) 149,522 (24.0)
       Diabetes mellitus 135,691 (16.3) 1,225 (16.5) 33,038 (16.3) 101,428 (16.3)
       Hyperlipidemia 280,907 (33.8) 2,571 (34.7) 69,941 (34.5) 208,395 (33.5)
      Charlson comorbidity index
       Mean±SD 1.0±1.5 1.0±1.5 1.0±1.5 1.0±1.5
       0-4 797,495 (95.9) 7,138 (96.2) 194,346 (96.0) 596,011 (95.8)
       ≥5 34,407 (4.1) 279 (3.8) 8,120 (4.0) 26,008 (4.2)
      Type of vaccination
       ChAd 1,317 (0.2) 4 (0.1) 301 (0.2) 1,012 (0.2)
       ChAd/ChAd 24,550 (3.0) 194 (2.6) 5,690 (2.8) 18,666 (3.0)
       ChAd/ChAd/ChAd 4 (0.0) 1 (0.0) (0.0) 3 (0.0)
       ChAd/ChAd/mRNA-1273 84,003 (10.1) 978 (13.2) 23,133 (11.4) 59,892 (9.6)
       ChAd/ChAd/BNT 47,881 (5.8) 502 (6.8) 14,207 (7.0) 33,172 (5.3)
       ChAd/mRNA-1273 3 (0.0) - 2 (0.0) 1 (0.0)
       ChAd/mRNA-1273/mRNA-1273 4 (0.0) - - 4 (0.0)
       ChAd/BNT 12,038 (1.5) 97 (1.3) 3,169 (1.6) 8,772 (1.4)
       ChAd/BNT/mRNA-1273 191 (0.0) 1 (0.0) 54 (0.0) 136 (0.0)
       ChAd/BNT/BNT 25,677 (3.1) 282 (3.8) 7,934 (3.9) 17,461 (2.8)
       Ad26 2,428 (0.3) 15 (0.2) 320 (0.2) 2,093 (0.3)
       Ad26/BNT 2 (0.0) - - 2 (0.0)
       mRNA-1273 3,607 (0.4) 10 (0.1) 951 (0.5) 2,646 (0.4)
       mRNA-1273/ChAd 1 (0.0) - - 1 (0.0)
       mRNA-1273/mRNA-1273 113,777 (13.7) 1,084 (14.6) 31,282 (15.5) 81,411 (13.1)
       mRNA-1273/mRNA-1273/mRNA-1273 17,181 (2.1) 206 (2.8) 4,887 (2.4) 12,088 (1.9)
       mRNA-1273/mRNA-1273/BNT 1,266 (0.2) 7 (0.1) 410 (0.2) 849 (0.1)
       mRNA-1273/BNT 2,142 (0.3) 23 (0.3) 537 (0.3) 1,582 (0.3)
       BNT 15,368 (1.9) 82 (1.1) 1,818 (0.9) 13,468 (2.2)
       BNT/ChAd 3 (0.0) - 1 (0.0) 2 (0.0)
       BNT/ChAd/BNT 1 (0.0) - - 1 (0.0)
       BNT/Ad26 1 (0.0) - 1 (0.0) -
       BNT/mRNA-1273 2 (0.0) - - 2 (0.0)
       BNT/BNT 292,703 (35.2) 2,623 (35.4) 70,483 (34.8) 219,597 (35.3)
       BNT/BNT/mRNA-1273 560 (0.1) 4 (0.1) 134 (0.1) 422 (0.2)
       BNT/BNT/BNT 139,382 (16.8) 1,303 (17.6) 37,152 (18.4) 100,927 (16.2)
      Vaccine doses
       No vaccination 47,809 (5.8) - - 47,809 (7.7)
       1st dose only 22,720 (2.7) 111 (1.5) 3,390 (1.7) 19,219 (3.1)
       2nd dose 445,222 (53.5) 4,021 (54.2) 111,165 (54.9) 330,036 (53.1)
       3rd dose 316,151 (38.0) 3,285 (44.3) 87,911 (43.4) 224,955 (36.2)
      Period Dose 1 Dose 2 Dose 3 Combined effect
      Control period 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
      Day 0 1.35 (1.30, 1.40) 1.53 (1.48, 1.59) 1.60 (1.51, 1.68) 1.47 (1.44, 1.50)
      Day 1 to 42 1.19 (1.18, 1.20) 1.15 (1.14, 1.16) 1.26 (1.24, 1.28) 1.17 (1.17, 1.18)
      Risk-period (day) Dose 1 Dose 2 Dose 3 Combined effect
      1 to 7 1.37 (1.35, 1.39) 1.77 (1.74, 1.79) 1.72 (1.68, 1.75) 1.59 (1.57, 1.60)
      8 to 14 1.42 (1.40, 1.44) 1.02 (1.00, 1.04) 0.94 (0.91, 0.97) 1.18 (1.17, 1.20)
      15 to 28 1.07 (1.06, 1.09) 1.03 (1.02, 1.04) 0.95 (0.92, 0.98) 1.04 (1.03, 1.05)
      29 to 42 1.03 (1.01, 1.05) 1.00 (0.99, 1.02) 0.89 (0.83, 0.94) 1.01 (1.00, 1.02)
      Subgroup Dose 1
      		 Dose 2
      		 Dose 3
      		 Combined dose
      Day 0 Day 1-42 Day 0 Day 1-42 Day 0 Day 1-42 Day 0 Day 1-42
      Age (yr)
       18-29 1.32 (1.22, 1.43) 1.25 (1.22, 1.27) 1.48 (1.37, 1.60) 1.16 (1.14, 1.18) 1.58 (1.33, 1.87) 2.19 (2.09, 2.29) 1.42 (1.34, 1.49) 1.23 (1.21, 1.25)
       30-39 1.53 (1.40, 1.67) 1.36 (1.33, 1.38) 1.69 (1.55, 1.84) 1.28 (1.26, 1.30) 1.83 (1.50, 2.24) 1.91 (1.81, 2.03) 1.62 (1.53, 1.72) 1.33 (1.31, 1.35)
       40-49 1.53 (1.41, 1.66) 1.22 (1.20, 1.25) 1.72 (1.59, 1.86) 1.27 (1.25, 1.30) 1.31 (1.08, 1.57) 2.01 (1.91, 2.10) 1.60 (1.52, 1.69) 1.28 (1.26, 1.30)
       50-59 1.47 (1.35, 1.59) 1.13 (1.11, 1.15) 1.92 (1.77, 2.07) 1.14 (1.12, 1.16) 1.86 (1.66, 2.09) 1.59 (1.53, 1.66) 1.73 (1.65, 1.82) 1.18 (1.16, 1.20)
       60-69 1.23 (1.11, 1.36) 0.99 (0.97, 1.02) 1.53 (1.40, 1.68) 1.02 (0.99, 1.04) 1.73 (1.57, 1.90) 1.03 (1.00, 1.07) 1.48 (1.40, 1.56) 1.01 (1.00, 1.03)
       70-79 0.70 (0.58, 0.83) 0.97 (0.94, 1.00) 0.78 (0.66, 0.92) 0.98 (0.95, 1.00) 1.37 (1.19, 1.57) 0.96 (0.92, 1.00) 0.92 (0.84, 1.01) 0.97 (0.95, 0.99)
       ≥80 0.45 (0.33, 0.60) 0.92 (0.87, 0.96) 0.54 (0.41, 0.70) 0.96 (0.92, 1.00) 1.53 (1.26, 1.85) 0.96 (0.91, 1.01) 0.77 (0.67, 0.88) 0.95 (0.92, 0.98)
      Sex
       Male 1.48 (1.40, 1.58) 1.11 (1.10, 1.13) 1.65 (1.56, 1.75) 1.14 (1.13, 1.16) 1.74 (1.60, 1.89) 1.18 (1.15, 1.22) 1.60 (1.54, 1.66) 1.13 (1.12, 1.15)
       Female 1.28 (1.22, 1.34) 1.23 (1.21, 1.24) 1.47 (1.41, 1.54) 1.15 (1.14, 1.16) 1.52 (1.42, 1.62) 1.30 (1.28, 1.33) 1.40 (1.36, 1.44) 1.19 (1.19, 1.20)
      Comorbidities
       Hypertension 1.16 (1.07, 1.25) 1.06 (1.04, 1.08) 1.29 (1.19, 1.39) 1.06 (1.04, 1.08) 1.63 (1.50, 1.77) 0.98 (0.95, 1.01) 1.33 (1.27, 1.39) 1.05 (1.04, 1.06)
       Diabetes mellitus 1.16 (1.05, 1.28) 1.06 (1.04, 1.08) 1.26 (1.15, 1.38) 1.07 (1.05, 1.09) 1.53 (1.38, 1.70) 0.96 (0.93, 0.99) 1.29 (1.22, 1.37) 1.05 (1.03, 1.06)
       Dyslipidemia 1.19 (1.11, 1.27) 1.11 (1.09, 1.12) 1.34 (1.26, 1.43) 1.09 (1.07, 1.10) 1.59 (1.47, 1.71) 1.04 (1.01, 1.06) 1.34 (1.29, 1.39) 1.09 (1.08, 1.10)
      Charlson comorbidity index
       0-4 1.37 (1.32, 1.42) 1.19 (1.18, 1.20) 1.55 (1.50, 1.61) 1.15 (1.14, 1.16) 1.60 (1.51, 1.69) 1.30 (1.28, 1.32) 1.48 (1.45, 1.52) 1.18 (1.17, 1.19)
       ≥5 0.96 (0.77, 1.18) 1.03 (0.99, 1.08) 1.04 (0.85, 1.28) 1.04 (1.00, 1.08) 1.62 (1.33, 1.97) 0.96 (0.90, 1.03) 1.16 (1.03, 1.31) 1.02 (0.99, 1.05)
      Type of vaccination
       ChAdOx1 1.41 (1.16, 1.70) 1.01 (0.97, 1.05) 1.36 (1.11, 1.67) 1.01 (0.97, 1.05) N/A N/A 1.39 (1.21, 1.60) 1.01 (0.98, 1.04)
       mRNA-1273 1.54 (1.42, 1.68) 1.59 (1.56, 1.62) 2.11 (1.95, 2.27) 1.28 (1.25, 1.30) 1.55 (1.21, 1.98) 1.78 (1.64, 1.94) 1.78 (1.69, 1.89) 1.43 (1.40, 1.45)
       BNT162b2 1.36 (1.29, 1.42) 1.14 (1.12, 1.15) 1.5 (1.43, 1.57) 1.19 (1.18, 1.20) 1.58 (1.46, 1.72) 1.41 (1.38, 1.45) 1.45 (1.41, 1.50) 1.19 (1.18, 1.20)
      Risk window RI (95% CI) for day 1-42
      Dose 1 Dose 2 Dose 3 Combined effect
      Days 21 1.29 (1.28, 1.30) 1.27 (1.26, 1.28) 1.31 (1.29, 1.33) 1.28 (1.28, 1.29)
      Days 28 1.23 (1.22, 1.25) 1.21 (1.20, 1.22) 1.28 (1.26, 1.31) 1.23 (1.22, 1.24)
      Days 35 1.20 (1.20, 1.21) 1.17 (1.17, 1.18) 1.27 (1.25, 1.29) 1.20 (1.19, 1.20)
      Days 42 1.19 (1.18, 1.20) 1.15 (1.14, 1.16) 1.26 (1.24, 1.28) 1.17 (1.17, 1.18)
      Days 49 1.18 (1.17, 1.19) 1.13 (1.12, 1.14) 1.26 (1.24, 1.28) 1.16 (1.15, 1.17)
      Days 56 1.17 (1.16, 1.18) 1.11 (1.11, 1.12) 1.27 (1.25, 1.29) 1.15 (1.14, 1.15)
      Days 63 1.16 (1.15, 1.17) 1.10 (1.10, 1.11) 1.27 (1.25, 1.29) 1.14 (1.13, 1.14)
      Table 1. Characteristics of patient demographics in relation to the incidence of lymphadenopathy during the risk and control periods after coronavirus disease 2019 vaccination

      Values are presented as number (%).

      ChAd, ChAdOx1; BNT, BNT162b2; Ad26, Ad26.COV2.S; SD, standard deviation.

      Table 2. Risk of lymphadenopathy by coronavirus disease 2019 vaccination

      Values are presented as relative incidence (95% confidence interval).

      Table 3. The risk of developing lymphadenopathy after coronavirus disease 2019 vaccination by time since vaccination

      Values are presented as relative incidence (95% confidence interval).

      Table 4. Subgroup analysis on the risk of lymphadenopathy after coronavirus disease 2019 vaccination

      Values are presented as relative incidence (95% confidence interval).

      N/A, not available.

      Table 5. Sensitivity analysis of lymphadenopathy risk by the length of the risk window

      RI, relative incidence; CI, confidence interval.

      Table 1.

      Table 2.

      Table 3.

      Table 4.

      Table 5.

      Epidemiol Health : Epidemiology and Health
      © Korean Society of Epidemiology.
      TOP